ABSTRACT: As a continuation of our previous report on the cytostatic activity for several halogenated thieno [3,2-d] 
Introduction
Pyrrolopyrimidines exist as two regioisomers, specifically pyrrolo [2,3-d] pyrimidine and pyrrolo [3,2-d] pyrimidine and are more commonly referred to as 7-deazapurine and 9-deazapurine respectively ( Figure 1) . 1 Due to a close resemblance to the purines, the pyrrolopyrimidine scaffold has found pharmacological utility as a purine isostere. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The 7-deazapurines ( Figure 1a ) are naturally occurring and widely used in drug design primarily due to their propensity to be ribosylated. Echiguanine B and Tubercidin are two examples of naturally occurring 7-deazapurines exhibiting anticancer properties ( Figure   1a ). . 33 In an effort to further explore these findings with an alternate scaffold, we opted to synthesize the analogous series of halogenated pyrrolo [3,2-d] pyrimidines. Once in hand, the toxicity of each pyrrolo [3,2- d]pyrimidine was then tested against three cancer cell lines (L1210, CEM and HeLa). [35] [36] [37] [38] [39] . Preparation of the sodium salt, followed by heating with phenylphosphonic dichloride (PhPOCl 2 ) at 170-175 ˚C gave 1 in a 60% yield. [35] [36] [37] [38] [39] Iodination of 1 using N-iodisuccinimide (NIS) in tetrahydrofuran (THF) at room temperature yielded the iodo analogue 2 in a 54% yield. 40 Attempts to protect the 5-NH of 2 with tert-butoxycarbonyl (Boc) in order to evaluate the effect of the NH on the biological activity of 2 failed due to the instability of the Boc protecting group during the subsequent silica gel purification. Alternatively, Boc protection of 1 was attempted using Boc 2 O in the presence of 4-dimethylaminopyridine (DMAP) at room temperature to give 6 in 65% yield. 41 Along with compounds in Scheme 1 and Scheme 2, three additional compounds,
12 and 9-deaza-2ˊ-deoxynucleosides 13 and 14 ( Figure 3 ) were also tested. While 12
helped evaluate the effect of a substituent other than OBn at C2, the C-nucleosides 34 
13
and 14 were tested owing to past [2] [3] [4] [5] [6] [7] [8] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] and recent 57 interest in the pharmacological properties of 9-deazanucleosides. The syntheses of compounds shown in Figure 3 have been reported by our group but their antiproliferative properties had not been previously evaluated.
34,58
Figure 3: Intermediate 12 and 9-deaza-2'-deoxynucleosides 13 and 14.
34
In vitro cell growth inhibition. The cytotoxic activities of several compounds described above were first assessed in three cultured tumor cell models: L1210, a mouse lymphocytic leukemia cell line 59 , CCRF-CEM 60 , an acute lymphoblastic leukemia cell line, and HeLa, a human cancer cell line derived from a human cervical adenocarcinoma. [61] [62] Comparisons of resolved IC 50 values (Table 1) 34 led to a marginal loss of activity indicating that an OBn group at C2 is not crucial for cytostatic activity and can be replaced. In order to evaluate the effect of the C7 iodine, the iodo analogue of 12 was sought, however all attempts at iodination failed due to the presence of 5-NH. 34 The ketone or amide groups, as found in 5, 7 and 8, do not impart activity against any cancer cell line tested, which is consistent with our previous studies on the thieno [3,2-d] pyrimidines. Similarly, the C-nucleosides 13 and 14 were both inactive and exhibited no cytotoxicity. 34 However, an interesting discovery resulting from examining various intermediates was the very modest cytotoxicity observed for the 2,4-bis-O-benzyl-5-nitro-6-dimethylaminovinyl pyrimidine (11). In summary, the antiproliferative activities of the halogenated-fused pyrimidines highlight the potential of reactive species as therapeutically useful scaffolds. Previously these types of covalent modifiers had been considered undesirable [65] [66] [67] [68] [69] [70] [71] [72] due to their chemically labile nature, however the renewed interest in such compounds [73] [74] [75] have shown they may be exploited to treat cancer in a novel and effective manner. AcOH (50 mL), Zinc dust (stabilized) (2 g) was added in two lots of 1g with an interval of 1 h. Upon overnight stirring the yellow slurry changed to a pale yellow to off-white slurry which was filtered and the filtrate concentrated in vacuo to obtain brown syrup.
Conclusions. We have identified interesting
The product was precipitated from the brown syrup using ethanol to obtain 4 as white solid (0.6 g, 89.8%). The spectral data agrees with reported data. 38 The product was purified using column chromatography eluting with 9:1 then 3:1 hexanes/ EtOAc to obtain 1 as an off-white solid (1.50 g, 7.9 mmol, 60%). R f 0. Cl).
7-Iodo-pyrrolo[3,2-d]pyrimidine-2,4-dione (7):
(500 mg, 3.31 mmol) was suspended in anhydrous DMF (10 mL) under N 2 atmosphere and cooled to -10 to -5 °C. To this slurry, N-iodosuccinimide (894 mg, 3.97 mmol) was added and the mixture stirred for 2 h at -10 to -5 °C, at which point the DMF was removed in vacuo to provide a brown sticky solid. The product was crystallized from the residue using 50% EtOH (6 mL) to give 7 (800 mg, 87.2%) as a yellow solid. Mp >300 
7-Iodo-1,3,5-tris-methoxymethyl-1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-dione (8):
A solution of 5 (200 mg, 0.72 mmol) in anhydrous DMF (5 mL) was cooled on ice under N 2 atmosphere to which 60% suspension of NaH in oil (130 mg, 3.25 mmol) was added and stirred for 15 min. The ice was removed and the mixture stirred at room temperature for an additional 15 min at which point CH 3 OCH 2 Cl (0.19 mL, 2.53 mmol) was added dropwise over 15 min. The reaction mixture was stirred for 30 min on ice after which water (5 mL) was added followed by extraction with CH 2 Cl 2 . The organic layer was washed with brine and dried over MgSO 4 . The organic layer was concentrated in vacuo and loaded on silica. The product was purified using column chromatography eluting with 9:1 and 4:1 hexanes/EtOAc to obtain product 8 as off-white solid (178 mg, 60% µM and 1.75 µM, respectively. After 48 h, the cells were then collected and the cellular fractions undergoing early apoptotic, late apoptotic/necrotic, and necrotic cell death were measured by staining with Annexin V and 7-amino-actinomycin D (7-AAD) using the BD Pharmingen PE Annexin V Apoptosis Detection Kit I (BD Pharmingen) as described. 77 All flow cytometry analyses required for cell cycle distribution and apoptosis assays were performed at the University of Maryland Greenebaum Cancer
Center Shared Flow Cytometry Facility.
